MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
66.62
+0.39
+0.59%
After Hours: 69.00 +2.38 +3.57% 16:10 12/05 EST
OPEN
66.36
PREV CLOSE
66.23
HIGH
67.00
LOW
64.84
VOLUME
386.60K
TURNOVER
--
52 WEEK HIGH
68.80
52 WEEK LOW
19.45
MARKET CAP
4.79B
P/E (TTM)
-18.5349
1D
5D
1M
3M
1Y
5Y
1D
Kymera Therapeutics To Announce Results From BroADen Phase 1b Clinical Trial Evaluating KT-621, Oral STAT6 Degrader, In Patients With Moderate To Severe AD On December 8
Benzinga · 1h ago
KYMERA THERAPEUTICS TO ANNOUNCE KT-621 BROADEN PHASE 1B ATOPIC DERMATITIS TRIAL RESULTS ON DECEMBER 8, 2025
Reuters · 1h ago
Piper Sandler Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)
TipRanks · 2d ago
Kymera Therapeutics’ KT-621: Promising Potential in Atopic Dermatitis with Significant Upside
TipRanks · 4d ago
Weekly Report: what happened at KYMR last week (1124-1128)?
Weekly Report · 4d ago
Kymera (KYMR) Q3 2025 Earnings Call Transcript
NASDAQ · 11/27 22:50
Kymera Therapeutics Price Target Raised to $80.00/Share From $68.00 by Truist Securities
Dow Jones · 11/26 18:14
Kymera Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 11/26 18:14
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.